Skip to main content

Page last checked

Being studied in people · not FDA-approved

Eloralintide

Also called LY3841136.

Eloralintide is an experimental weekly shot for weight loss. It works on amylin receptors, not GLP-1.

What matters first

Why people look it up
Researchers are studying Eloralintide for weight loss.
What the evidence shows
A Phase 2 trial reported average weight loss across six study groups. A larger Phase 3 trial is recruiting, so there is no approved dose or launch date.
Dose status
Trials tested Eloralintide at 1–9 mg once a week for 48 weeks in Phase 2; four fixed-dose groups and two study-set paths ending at 9 mg. There is no FDA-approved dose or dosing label. Every number below is a trial arm, not a treatment schedule.

Evidence snapshot

Published human trial

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human trial regimens6 regimens · not a schedule
Safety evidence
3 listed safety findingsCommon and serious effects shown apart
Sources
6 cited sourcesMedical review complete · 2026-09-07
Open the shareable evidence image
Eloralintide at a glance: published human trial, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how it works · how good the evidence is · questions

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about Eloralintide

Eloralintide is an experimental weekly shot for weight loss. It works on amylin receptors, not GLP-1. In a 263-person Phase 2 trial, average weight change after 48 weeks ranged from 9.4% to 20.1% across six study groups, compared with 0.4% for placebo. A larger Phase 3 trial is recruiting, so there is no approved dose or launch date.

Eloralintide research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourceHuman trial
FDA approvalNot FDA-approved
Studied dosing1–9 mg once weekly for 48 weeks in Phase 2; four fixed-dose groups and two study-set paths ending at 9 mg — from clinical trials
PresentationEloralintide has no approved vial or mixing instructions; its trials use prepared study injections.

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

How Eloralintide works

Eloralintide acts at amylin. Here is what that means.

Amylin is not a gut hormone, and this is the one class here that does not act on a gut hormone receptor at all. Your pancreas releases amylin alongside insulin, and its job is to say the meal is over. Natural amylin clumps together and clears fast. A long-acting version is rebuilt to be stable enough for a weekly injection. It holds a signal that normally lasts one meal across several days.

◆ Receptor targets1 of 4 · amylin
5What each receptor does — 5 rows in the data table
Receptors targeted by Eloralintide, and what each receptor does
ReceptorEloralintideWhat it does
GLP-1not targeted—
GIPnot targeted—
Glucagonnot targeted—
Amylintargetedarea postrema and hindbrainAmylin works mainly on a small brainstem region that sits outside the blood-brain barrier and samples the blood directly. Switching it on produces fullness — the feeling that ends a meal — rather than damping hunger in the gaps between meals. That is a different lever from the gut-hormone one.
Gastric and islet effectstargetedAmylin also slows stomach emptying and holds back the rise in glucagon after a meal, working alongside insulin on the same meal rather than repeating it.

The same four receptor groups are shown for every drug, so the differences are easy to compare. Targets come from the drug class. Any result specific to Eloralintide comes from the cited sources.

Amylin and GLP-1 signals help fullness in different ways. That is why researchers combine the two instead of only raising one dose. The side effects can also differ, so results from a GLP-1 drug do not automatically carry over to an amylin drug.

What the evidence for Eloralintide is

These numbers come from a study in people that was published in a peer-reviewed journal. The drug or dose may still be experimental and may not have FDA approval.

Human trial

The trial behind the numbers

48-week Phase 2 weight-management trial · 263 participants · 48 weeks

NCT06230523 — 48-week Phase 2 Eloralintide trial · retrieved 2026-08-29

What it establishes
The study gave known doses to a defined group, monitored what happened and compared the results with another group.
What it does not establish
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Read each result with the study length, dose and number of participants. Results from separate trials are not a direct comparison because the people and study designs differ.

What each dose produced in the trial

These are the doses the trial gave and the weight change it reported for each one. It is a record of one experiment, not a schedule — no regulator has reviewed any of these doses.

◆ 48-week Phase 2 weight-management trial263 participants · 48 weeks

Average weight change from the start of the trial, by weekly dose · the dashed rule marks placebo

7Exact trial values — 7 rows in the data table
Eloralintide — 48-week Phase 2 weight-management trial: average weight change from the start for each dose group
Once-weekly doseStudy groupAverage weight changeWhat the paper notes
1 mgActive−9.4%—
3 mgActive−12.4%—
6 mgActive−17.6%—
9 mgActive−20.1%—
9 mgActive−19.9%—
9 mgActive−16.5%—
PlaceboControl−0.4%The group used to compare every active dose

What the source does not report for each dose group

These are least-squares mean changes from baseline posted for the six randomized groups. They are group averages, not a personal forecast. The three groups ending at 9 mg had different study paths and remain separate.

Source: NCT06230523 — 48-week Phase 2 Eloralintide trial · retrieved 2026-08-29 · every value is quoted from that paper. Trial results describe averages across a study population, not an individual outcome.

Some bars are missing on purpose. Where the paper gives a range across arms instead of a figure per arm, that arm is left unplotted rather than filled in with a guess. The dashed line marks the placebo arm, so the part of each bar past it is the part the trial puts down to the drug rather than to being in a study.

How the trial reached those doses, step by step →

Where Eloralintide is in clinical trials

21 registered studies; the program has reached phase 3, and 12 are still enrolling.

The soonest a running study expects to finish measuring people is October 2026. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.

  • Phase 3Recruiting

    A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    Eli Lilly and Company · Sleep Apnea, Obstructive, Obesity · 800 participants planned · started February 2026

    Main measurement due March 2028 (sponsor estimate)

    NCT07369011 on ClinicalTrials.gov

  • Phase 3Recruiting

    A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    Eli Lilly and Company · Overweight, Obesity · 900 participants planned · started February 2026

    Main measurement due June 2028 (sponsor estimate)

    NCT07392190 on ClinicalTrials.gov

  • Phase 3Recruiting

    Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

    Eli Lilly and Company · Osteoarthritis, Overweight or Obesity · 900 participants planned · started February 2026

    Main measurement due March 2028 (sponsor estimate)

    NCT07353931 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-07

Every compound we track, and what stage each one has reached →

Regulatory status

Eloralintide is investigational.

It has no prescribing label or approved dose. The amounts below belong to monitored study groups and are not a schedule for personal use. A recruiting Phase 3 study has no results yet.

Full regulatory tracker →

Where to go next on Eloralintide

The related pages keep each topic with its evidence.

Eloralintide dosing evidence, without an approved schedule

1 published eloralintide dose value, each linked to the original source.

Which eloralintide reactions warrant medical attention

No boxed warning applies to eloralintide, which reflects the review it has not had.

The source-checked brenipatide entry, beyond the eloralintide one

No regulator has approved brenipatide — beyond eloralintide.

The source-checked enicepatide entry, beyond the eloralintide one

No regulator has approved enicepatide — beyond eloralintide.

MariTide in the full list, alongside eloralintide

No published half-life for MariTide, cited apart from eloralintide.

Take the eloralintide arithmetic to any other vial

Concentration, units per draw and draws per vial, including Eloralintide

What the VK2735 page carries, separate from eloralintide

4 sourced VK2735 reactions, on its own page, separate from eloralintide.

Pemvidutide on its own page, separate from eloralintide

Pemvidutide has published human trial data, separate from eloralintide.

Mazdutide in the full list, alongside eloralintide

No published half-life for mazdutide, cited apart from eloralintide.

Zenagamtide in the full list, alongside eloralintide

No published half-life for zenagamtide, cited apart from eloralintide.

Safety notes

  • Investigational compound — no approved dose or prescribing label exists
  • Side-effect rates varied widely across the six Phase 2 study groups
  • The recruiting Phase 3 trial has no results or approved launch date

Questions about Eloralintide

Is Eloralintide FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Eloralintide taken?

By injection under the skin, once a week. The dosing page has every step, with the source on each row.

How does Eloralintide differ from the other compounds in this class?

It acts at amylin. Adding or removing a receptor changes the effect. It also changes how much people can tolerate. These molecules are not swappable at the same number of milligrams. Comparing them milligram for milligram is the most common mistake in this category.

The nearest alternatives act elsewhere:

  • Tirzepatide (GIP + GLP-1)
  • Semaglutide (GLP-1 alone)
  • Liraglutide (GLP-1 alone)
  • Retatrutide (GIP + GLP-1 + glucagon)
  • Survodutide (glucagon + GLP-1)
  • Mazdutide (glucagon + GLP-1)
  • VK2735 (GIP + GLP-1)
  • Zenagamtide (GLP-1 + amylin)
  • Pemvidutide (glucagon + GLP-1)
  • Brenipatide (GIP + GLP-1)
  • Enicepatide (GIP + GLP-1)
  • MariTide (GIP + GLP-1)

What is not known about Eloralintide?

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

For this compound specifically: These are least-squares mean changes from baseline posted for the six randomized groups. They are group averages, not a personal forecast. The three groups ending at 9 mg had different study paths and remain separate.

Is there a Eloralintide dosing schedule on this site?

Not a schedule — there is no approved schedule to publish here. What you get instead is the trial dosing program: the doses each arm received and how the protocol worked up to them. The studied range was 1–9 mg once a week for 48 weeks in Phase 2; four fixed-dose groups and two study-set paths ending at 9 mg. See what the trials tested.

6primary sources, each with the day we read it — open the documents used on this page